Substantially pure histidine-linked protein polymer conjugates |
| In one aspect, the present invention includes substantially pure protein-polymer conjugates. The ... |
|
Crosslinked polymer compositions and methods for their use |
| The present invention discloses a crosslinked polymer composition comprising a first synthetic ... |
|
Conjugation of polypeptides |
| OF THE INVENTION It is the object of the invention to provide polypeptide conjugates with reduced ... |
|
High molecular weight polymer-based prodrugs |
| OF THE INVENTION A. THE PRODRUGS In most aspects of the invention, the prodrug compositions of the ... |
|
Non-antigenic amine derived polymers and polymer conjugates |
| In one aspect of the invention, there are provided amine-based polymer intermediates having the ... |
|
Biodegradable high molecular weight polymeric linkers and their conjugates |
| The present invention includes compounds of the formula: (D).sub.n --M--(R.sub.1).sub.m (I) wherein ... |
|
Modified polypeptides with high activity and reduced allergenicity |
| OF THE INVENTION The modified polypeptide of the present invention is represented by the formula: A... |
|
Poly(ethylene glycol) derivatives with proximal reactive groups |
| OF THE INVENTION The terms "group," "functional group," "moiety," "active moiety," "reactive site,"... |
|
Devices for cloaking transplanted cells |
| A variety of devices can be used to contain or cloak a source of a therapeutic substance, often ... |
|
Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| In one aspect of the invention, compounds of Formula (I) are provided: ##STR6## wherein: J is ##STR7... |
|
|
Antiviral polynucleotide conjugates
| Details |
Inventors: Climie, Shane; Ma, Michael;
Assignee: Allelix Biopharmaceuticals, Inc. (Missisauga, CA)
Primary Examiner: Jones; W. Gary
Assistant Examiner: Houtteman; Scott
Attorney, Agent or Firm: Foley & Lardner
The herpes simplex virus encodes ICP4, a DNA binding protein. ICP4-binding duplexed structures having significantly enhanced stability under physiological conditions are described. The structures are provided in the form of polynucleotide conjugates capable of adopting a duplexed structure, in which annealable polynucleotide strands are coupled covalently at one or both ends through a chemical linker which establishes a stabilizing bridge between strands. The present polynucleotide conjugates have therapeutic utility against viral infection as the polynucleotide strands thereof define a binding site for a viral regulatory protein, thereby inactivating the protein and preventing viral replication from occurring. |
|
DETAILED DESCRIPTION OF THE INVENTION The present invention provides polynucleotide conjugates characterized by the properties of ligand binding and enhanced stability. In the present specification, the term "enhanced stability", unless otherwise stated, refers to the superior thermal stability of a polynucleotide conjugate relative to its unlinked counterpart, as measured using melting temperature (Tm) assays established in the art. The term "ligand" is used herein with reference to agents that bind measurably, in the context of an assay appropriate for that measurement, to nucleic acid structures, principally double- stranded structures but also single-stranded structures. The term ligand is thus intended to embrace such agents as proteins, including proteins that regulate genetic processes such as transcription and translation, as well as non-protein entities including but not limited to intercalating agents and nucleic acid binding antibiotics as well as other nucleic acids. The term "ligand-binding" is thus used with reference to polynucleotide conjugates that adopt a structure that is bound measurably by a ligand against which the conjugate is targeted. In providing duplexed structures of enhanced stability, the present invention permits the use of double-stranded polynucleotide structures in a wide variety of applications not previously possible as a result of prior stability problems. Because the chemically linked duplexed structures of the present invention are substantially more stable than their unlinked counterparts under physiological conditions, for example, therapeutic applications for duplexed structures are now feasible. In addition, it will be appreciated that the stability-enhancing effect of the chemical linker can be exploited to eliminate polynucleotide regions that are otherwise required to permit formation and maintenance of the desired duplexed structure in vitro and in vivo. Further, the chemical linkers employed to form the present polynucleotide conjugates are substantially resistant to nuclease digestion, a contributing factor to the instability of unlinked polynucleotide fragments in vivo
|
|